Browsing: partnerships

Dubai-based toll gate operator Salik reported a net profit of AED 1.16 billion ($315.9 million) for 2024, with EBITDA reaching AED 1.6 billion, reflecting a 13.6% year-on-year increase.

Paytm, through its subsidiary Paytm Cloud Tech, plans to establish operations in the UAE, Saudi Arabia, and Singapore to capitalise on its tech-enabled merchant payments and financial services in similar international markets. The company will also seek local licences and partnerships.

Globalpharma, the leading pharmaceutical manufacturer in the UAE and a fully owned subsidiary of Dubai Investments PJSC, revealed its ambitious plans for 2025, highlighting the launch of 25 new and innovative products across key therapeutic areas.

Burjeel, a UAE-based hospital operator, has acquired a healthcare facility in Mecca through its Saudi subsidiary.

Abu Dhabi Investment Office (ADIO) has signed multiple agreements to explore manufacturing opportunities in line with the emirate’s focus on sustainable growth and economic diversification. The agreements were formalised during the Procurement Forum at the first Abu Dhabi Business Week, held from 4-6 December. The forum highlighted the role of the private sector in shaping public sector procurement and driving economic transformation.

The Digital Dubai Authority, responsible for advancing the digital transformation of the Emirate, has entered…

The Fujairah Department of Industry and Economy hosted the Fujairah-Japan Forum, a key event aimed…

Emirates Development Bank (EDB), the primary financial driver of economic growth and industrial progress in the UAE, showcased its unique perspective on financing national development, fostering SME resilience, and adapting to the evolving treasury landscape at the ACT Middle East Treasury Summit 2024, which concluded today in Dubai.

Abu Dhabi state investor Mubadala and CBC Group have agreed to acquire UCB’s Chinese neurology and allergy business for $680M. This deal, expected to close in Q4 2024 pending regulatory approval, includes UCB’s neurology products (Keppra, Vimpat, Neupro) and allergy medications (Zyrtec, Xyzal), as well as the Zhuhai manufacturing site. UCB confirmed that this transaction will not affect its 2024 forecasts.

Investors from Saudi Arabia and the UK are exploring growth opportunities as the Kingdom’s sports sector aims for a market size of $23B.